Merck & Co Inc

NYSE: MRK
$95.00
-$3.36 (-3.4%)
Real Time Data Delayed 15 Min.

MRK Articles

Merck is scheduled to release its fourth-quarter before the markets open on Friday, and analysts are looking for solid top and bottom line growth.
The January 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
24/7 Wall St. has put together a preview of those Dow Jones industrials scheduled to report their quarterly results this week, including Apple, Exxon and Microsoft.
24/7 Wall St. has ranked these Dow Stocks on their performance thus far in 2019, as of Wednesday’s closing price. We have also added in some additional color on these companies as well.
The top analyst upgrades, downgrades and initiations seen on Wednesday included Alphabet, Amazon.com, Dell Technologies, IBM, International Paper, Merck, Pfizer, Tesla, Teva Pharmaceutical and...
The December 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Merck shares were relatively unchanged early on Thursday after the firm announced that its blockbuster drug Keytruda reported a series of approvals in Japan.
See why preliminary 2019 consensus-based forecasting has offered up a likely target of 28,000 on the Dow Jones industrial average in 2019.
Investors love their dividends. So 24/7 Wall St. has tracked the Dogs of the Dow strategy for years now.
The December 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
The November 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
24/7 Wall St. takes a look at what is coming up in the FDA calendar regarding biotech and pharmaceutical companies expecting updates to their drug pipeline or other major events for the rest of 2018.
The November 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
The October 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with one major exception.
Judging by the most shorted stocks traded on the New York Stock Exchange between the October 15 and October 31 settlement dates, those sellers had become more selective.